The role of allostery in the ubiquitin-proteasome system

Critical Reviews in Biochemistry and Molecular Biology

Volumn 48, Issue 2, 2013, Pages 89-97

  Liu, Jin ^a   Nussinov, Ruth ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Allosteric; Allostery; Degradation; Molecular machine; Ubiquitin

Indexed keywords

PROTEASOME; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3;

ALLOSTERISM; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; CARDIOVASCULAR DISEASE; CATALYSIS; CRYSTAL STRUCTURE; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG TARGETING; HUMAN; METABOLIC DISORDER; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RING FINGER MOTIF; SUMOYLATION; UBIQUITINATION;

ANIMALS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN CONFORMATION; UBIQUITIN; UBIQUITIN-ACTIVATING ENZYMES; UBIQUITINATION;

EID: 84875591188     PISSN: 10409238     EISSN: 15497798     Source Type: Journal    
DOI: 10.3109/10409238.2012.742856     Document Type: Review

References (89)

1. Balakirev MY, Tcherniuk SO, Jaquinod M, et al. (2003). Otubains: a new family of cysteine proteases in the ubiquitin pathway. EMBO Rep 4:517-22
2. Bech-Otschir D, Helfrich A, Enenkel C, et al. (2009). Polyubiquitin substrates allosterically activate their own degradation by the 26S proteasome. Nat Struct Mol Biol 16:219-25
3. Bernier-Villamor V, Sampson DA, Matunis MJ, et al. (2002). Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1. Cell 108:345-56
4. Brzovic PS, Lissounov A, Christensen DE, et al. (2006). A UbcH5/ ubiquitin noncovalent complex is required for processive BRCA1- directed ubiquitination. Mol Cell 21:873-80
5. Capili AD, Lima CD. (2007). Taking it step by step: mechanistic insights from structural studies of ubiquitin/ubiquitin-like protein modification pathways. Curr Opin Struct Biol 17:726-35
6. Cavanaugh A, Huang Y, Breitwieser GE. (2012). Behind the curtain: cellular mechanisms for allosteric modulation of calcium-sensing receptors. Brit J Pharmacol 165:1670-7
7. Ceccarelli DF, Tang X, Pelletier B, et al. (2011). An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme. Cell 145:1075-87
8. Ciechanover A, Brundin P. (2003). The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 40:427-46
9. Coccetti P, Tripodi F, Tedeschi G, et al. (2008). The CK2 phosphorylation of catalytic domain of Cdc34 modulates its activity at the G1 to S transition in Saccharomyces cerevisiae. Cell Cycle 7:1391-401
10. da Fonseca PC, Morris EP. (2008). Structure of the human 26S proteasome: subunit radial displacements open the gate into the proteolytic core. J Biol Chem 283:23305-14
11. Das R, Mariano J, Tsai YC, et al. (2009). Allosteric activation of E2- RING finger-mediated ubiquitylation by a structurally defined specific E2-binding region of gp78. Mol Cell 34:674-85
12. Dou H, Buetow L, Hock A, et al. (2012a). Structural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl. Nat Struct Mol Biol 19:184-92
13. Dou H, Buetow L, Sibbet GJ, et al. (2012b). BIRC7-E2 ubiquitin conjugate structure reveals the mechanism of ubiquitin transfer by a RING dimer. Nat Struct Mol Biol 19:876-83
14. Duda DM, Borg LA, Scott DC, et al. (2008). Structural insights into NEDD8 activation of cullin-RING ligases: conformational control of conjugation. Cell 134:995-1006
15. Duda DM, Scott DC, Calabrese MF, et al. (2011). Structural regulation of cullin-RING ubiquitin ligase complexes. Curr Opin Struct Biol 21:257-64
16. Dupre S, Haguenauer-Tsapis R. (2001). Deubiquitination step in the endocytic pathway of yeast plasma membrane proteins: crucial role of Doa4p ubiquitin isopeptidase. Mol Cellular Biol 21:4482-94
17. Fisk HA, Yaffe MP. (1999). A role for ubiquitination in mitochondrial inheritance in Saccharomyces cerevisiae. J Cell Biol 145:1199-208
18. Gaczynska M, Osmulski PA. (2011). Atomic force microscopy of proteasome assemblies. Methods Mol Biol 736:117-32
19. Gaczynska M, Osmulski PA, Gao Y, et al. (2003). Proline- and argininerich peptides constitute a novel class of allosteric inhibitors of proteasome activity. Biochemistry 42:8663-70
20. Goodey NM, Benkovic SJ. (2008). Allosteric regulation and catalysis emerge via a common route. Nat Chem Biol 4:474-82
21. Gunasekaran K, Ma B, Nussinov R. (2004). Is allostery an intrinsic property of all dynamic proteins? Proteins 57:433-43
22. Herrmann J, Ciechanover A, Lerman LO, et al. (2004). The ubiquitin- proteasome system in cardiovascular diseases - a hypothesis extended. Cardiovasc Res 61:11-21
23. Hershko A. (2005). Early work on the ubiquitin proteasome system, an interview with Avram Hershko. Interview by CDD. Cell Death Differ 12:1158-61
24. Hofmann RM, Pickart CM. (1999). Noncanonical MMS2-encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell 96:645-53
25. Huang DT, Hunt HW, Zhuang M, et al. (2007). Basis for a ubiquitinlike protein thioester switch toggling E1-E2 affinity. Nature 445:394-8
26. Huang DT, Paydar A, Zhuang M, et al. (2005). Structural basis for recruitment of Ubc12 by an E2 binding domain in NEDD8's E1. Mol Cell 17:341-50
27. Jackson S, Xiong Y. (2009). CRL4s: the CUL4-RING E3 ubiquitin ligases. Trends Biochem Sci 34:562-70
28. Kar G, Keskin O, Gursoy A, Nussinov R. (2010). Allostery and population shift in drug discovery. Curr Opin Pharmacol 10:715-22
29. Karaca E, Tozluoglu M, Nussinov R, Haliloglu T. (2011). Alternative allosteric mechanisms can regulate the substrate and E2 in SUMO conjugation. J. Mol Biol 406:620-30
30. Karagoz GE, Duarte AM, Ippel H, et al. (2011). N-terminal domain of human Hsp90 triggers binding to the cochaperone p23. Proc Natl Acad Sci USA 108:580-5
31. Kenakin TP. (2012). Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Brit J Pharmacol 165:1659-69
32. Klinger PP, Schubert U. (2005). The ubiquitin-proteasome system in HIV replication: potential targets for antiretroviral therapy. Expert Rev Anti-infective Therapy 3:61-79
33. Komander D, Clague MJ, Urbe S. (2009). Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 10:550-63
34. Kumar S, Ma B, Tsai, CJ, et al. (2000). Folding and binding cascades: dynamic landscapes and population shifts. Protein Sci: Publ Protein Soc 9:10-19
35. Lamothe B, Besse A, Campos AD, et al. (2007). Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J Biol Chem 282:4102-12
36. Lander GC, Estrin E, Matyskiela ME, et al. (2012). Complete subunit architecture of the proteasome regulatory particle. Nature 482:186- 91
37. Lasker K, Forster F, Bohn S, et al. (2012). Molecular architecture of the 26S proteasome holocomplex determined by an integrative approach. Proc Natl Acad Sci USA 109:380-7
38. Leonard TA, Hurley JH. (2011). Regulation of protein kinases by lipids. Curr Opin Struct Biol 21:785-91
39. Li J, Post M, Volk R, et al. (2000). PR39, a peptide regulator of angiogenesis. Nat Med 6:49-55
40. Li W, Tu D, Li L, et al. (2009). Mechanistic insights into active siteassociated polyubiquitination by the ubiquitin-conjugating enzyme Ube2g2. Proc Natl Acad Sci USA 106:3722-7
41. Liu J, Nussinov R. (2008). Allosteric effects in the marginally stable von Hippel-Lindau tumor suppressor protein and allostery-based rescue mutant design. Proc Natl Acad Sci USA 105:901-6
42. Liu J, Nussinov R. (2009). The mechanism of ubiquitination in the cullin-RING E3 ligase machinery: conformational control of substrate orientation. PLoS Comput Biol 5:e1000527
43. Liu J, Nussinov R. (2010a). Molecular dynamics reveal the essential role of linker motions in the function of cullin-RING E3 ligases. J Mol Biol 396:1508-23
44. Liu J, Nussinov R. (2010b). Rbx1 flexible linker facilitates cullin-RING ligase function before neddylation and after deneddylation. Biophys J 99:736-44
45. Liu J, Nussinov R. (2011). Flexible cullins in cullin-RING E3 ligases allosterically regulate ubiquitination. J Biol Chem 286:40934-42
46. Lyumkis D, Doamekpor SK, Mario H, et al. (2013). Single-particle electron microscopy reveals extensive conformational variability of the Ltn1 E3 ligase, submitted
47. Ma B, Kumar S, Tsai CJ, et al. (1999). Folding funnels and binding mechanisms. Protein Eng 12:713-20
48. Ma B, Tsai CJ, Haliloglu T, et al. (2011). Dynamic allostery: linkers are not merely flexible. Structure 19:907-17
49. Mani A, Gelmann EP. (2005). The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol: OJ Amer Soc Clin Oncol 23:4776-89
50. Mao X, Li X, Sprangers R, et al. (2009). Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma. Leukemia: OJ Leukemia Soc Amer Leukemia Res Fund UK 23:585-90
51. Nalepa G, Rolfe M, Harper JW. (2006). Drug discovery in the ubiquitin- proteasome system. Nat Rev Drug Discov 5:596-613
52. Nussinov R, Tsai CJ, Csermely P. (2011). Allo-network drugs: harnessing allostery in cellular networks. Trends Pharmacol Sci 32:686-93
53. Nussinov R, Tsai CJ, Xin F, et al. (2012). Allosteric post-translational modification codes. Trends Biochem Sci 37:447-55
54. Ogunjimi AA, Briant DJ, Pece-Barbara N, et al. (2005). Regulation of Smurf2 ubiquitin ligase activity by anchoring the E2 to the HECT domain. Mol Cell 19:297-308
55. Orlicky S, Tang X, Neduva V, et al. (2010). An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase. Nat Biotechnol 28:733-7
56. Ozkan E, Yu H, Deisenhofer J. (2005). Mechanistic insight into the allosteric activation of a ubiquitin-conjugating enzyme by RING-type ubiquitin ligases. Proc Natl Acad Sci USA 102:18890-5
57. Pan Y, Tsai CJ, Ma B, et al. (2010). Mechanisms of transcription factor selectivity. Trends Genet 26:75-83
58. Papaleo E, Casiraghi N, Arrigoni A, et al. (2012). Loop 7 of e2 enzymes: an ancestral conserved functional motif involved in the e2-mediated steps of the ubiquitination cascade. PloS One 7:e40786
59. Papaleo E, Ranzani V, Tripodi F, et al. (2011). An acidic loop and cognate phosphorylation sites define a molecular switch that modulates ubiquitin charging activity in Cdc34-like enzymes. PLoS Comput Biol 7:e1002056
60. Pathare GR, Nagy I, Bohn S, et al. (2012). The proteasomal subunit Rpn6 is a molecular clamp holding the core and regulatory subcomplexes together. Proc Natl Acad Sci USA 109:149-54
61. Paul S. (2008). Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches. BioEssays: News Rev Mol Cellular Dev Biol 30:1172-84
62. Pickart CM. (2000). Ubiquitin biology: an old dog learns an old trick. Nat Cell Biol i2:E139-41
63. Pruneda JN, Littlefield PJ, Soss SE, et al. (2012). Structure of an E3:E2 approximately Ub complex reveals an allosteric mechanism shared among RING/U-box ligases. Mol Cell 47:933-42
64. Reverter D, Lima CD. (2005). Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex. Nature 435:687-92
65. Rual JF,Venkatesan K, HaoT, et al. (2005). Towards a proteome-scale map of the human protein-protein interaction network. Nature 437:1173-8
66. Ruschak AM, Slassi M, Kay LE, et al. (2011). Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 103:1007-17
67. Sanjo H, Zajonc DM, Braden R, et al. (2010). Allosteric regulation of the ubiquitin:NIK and ubiquitin:TRAF3 E3 ligases by the lymphotoxinbeta receptor. J Biol Chem 285:17148-55
68. Schulman BA, Harper JW. (2009). Ubiquitin-like protein activation by E1 enzymes: the apex for downstream signalling pathways. Nat Rev Mol Cell Biol 10:319-31
69. Souphron J, Waddell MB, Paydar A, et al. (2008). Structural dissection of a gating mechanism preventing misactivation of ubiquitin by NEDD8's E1. Biochemistry 47:8961-9
70. Spence J, Gali RR, Dittmar G, et al. (2000). Cell cycle-regulated modification of the ribosome by a variant multiubiquitin chain. Cell 102:67-76
71. Sprangers R, Li X, Mao X, et al. (2008). TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors. Biochemistry 47:6727-34
72. Tatham MH, Kim S, Jaffray E, et al. (2005). Unique binding interactions among Ubc9, SUMO and RanBP2 reveal a mechanism for SUMO paralog selection. Nat Struct Mol Biol 12:67-74
73. Tozluoglu M, Karaca E, Nussinov R, et al. (2010). A mechanistic view of the role of E3 in sumoylation. PLoS Comput Biol 6:e1000913.
74. Truong K, Su Y, Song J, Chen Y. (2011). Entropy-driven mechanism of an E3 ligase. Biochemistry 50:5757-66
75. Tsai CJ, Del Sol A, Nussinov R. (2009). Protein allostery, signal transmission and dynamics: a classification scheme of allosteric mechanisms. Mol Biosyst 5:207-16
76. Tsai CJ, Kumar S, Ma B, et al. (1999a). Folding funnels, binding funnels, and protein function. Protein Sci: Publ Protein Soc 8:1181-90
77. Tsai CJ, Ma B, Nussinov R. (1999b). Folding and binding cascades: shifts in energy landscapes. Proc Natl Acad Sci USA 96:9970-2
78. Tsai CJ, Nussinov R. (2011). Gene-specific transcription activation via long-range allosteric shape-shifting. Biochem J 439:15-25
79. Turner GC, Du F, Varshavsky A. (2000). Peptides accelerate their uptake by activating a ubiquitin-dependent proteolytic pathway. Nature 405:579-83
80. Ulrich HD, Jentsch S. (2000). Two RING finger proteins mediate cooperation between ubiquitin-conjugating enzymes in DNA repair. EMBO J 19:3388-97
81. Varshavsky A. (2011). The N-end rule pathway and regulation by proteolysis. Protein Sci: Publ Protein Soc 20:1298-1345
82. Wang J, Maldonado MA. (2006). The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol Immunol 3:255-61
83. Wang J, Schulman BA. (2009). (G2)Bringing an E2 to E3. Structure 17:916-7
84. Wenzel DM, Klevit RE. (2012). Following Ariadne's thread: a new perspective on RBR ubiquitin ligases. BMC Biol 10:24
85. Wiener R, Zhang X, Wang T. (2012). The mechanism of OTUB1- mediated inhibition of ubiquitination. Nature 483:618-22
86. Wood MR, Hopkins CR, Brogan JT, et al. (2011). ''Molecular switches'' on mGluR allosteric ligands that modulate modes of pharmacology. Biochemistry 50:2403-10
87. Xie Y, Varshavsky A. (1999). The E2-E3 interaction in the N-end rule pathway: the RING-H2 finger of E3 is required for the synthesis of multiubiquitin chain. EMBO J 18:6832-44
88. Yang Y, Kitagaki J, Wang H, et al. (2009). Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci 100:24-8
89. Zheng N, Schulman BA, Song L, et al. (2002). Structure of the Cul1- Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 416:703-9